Med-tech funding outlook improves as dealmaking acceleratesAn increase in the level of M&A activity and some sizeable financing rounds are encouraging signs for the med-tech investment environment, said Joey Mason, Life Sciences Venture Partner at Claret Capital Partners. And you're seeing a fairly decent bit of M&A activity, and if I'm looking for signs that the market improving, it's M&A and then some decent-sized financings, like the one we’ve seen with Neurent.” Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021Biopharma IPO activity through the first two quarters of 2026 totaled $5.77 billion, the strongest first-half showing since 2021's $13.49 billion. Bipartisan health bills get passing vote from US HouseIn a rapid-fire voting session late yesterday, the U.S. House suspended the rules to pass a slate of bipartisan health bills ranging from reducing animal testing in drug development to Medicare coverage of wheelchairs. The question now is whether the Senate will have the bipartisan will to pass the House bills before its scheduled Dec. 18 end of the legislative year.